1
|
Zeng Z, Li H, Li Q, Sun R, Zhang X, Zhang D, Zhu Q, Chen C. Quantitative measurement of acute myocardial infarction cardiac biomarkers by "All-in-One" immune microfluidic chip for early diagnosis of myocardial infarction. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2024; 315:124256. [PMID: 38615418 DOI: 10.1016/j.saa.2024.124256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 02/26/2024] [Accepted: 04/04/2024] [Indexed: 04/16/2024]
Abstract
Acute myocardial infarction (AMI) is a life-threatening condition with a narrow treatment window, necessitating rapid and accurate diagnostic methods. We present an "all-in-one" convenient and rapid immunoassay system that combines microfluidic technology with a colloidal gold immunoassay. A degassing-driven chip replaces a bulky external pump, resulting in a user-friendly and easy-to-operate immunoassay system. The chip comprises four units: an inlet reservoir, an immunoreaction channel, a waste pool, and an immunocomplex collection chamber, allowing single-channel flow for rapid and accurate AMI biomarker detection. In this study, we focused on cardiac troponin I (cTnI). With a minimal sample of just 4 μL and a total detection time of under 3 min, the chip enabled a quantitative visual analysis of cTnI concentration within a range of 0.5 ∼ 60.0 ng mL-1. This all-in-one integrated microfluidic chip with colloidal gold immunoassay offers a promising solution for rapid AMI diagnosis. The system's portability, small sample requirement, and quantitative visual detection capabilities make it a valuable tool for AMI diagnostics.
Collapse
Affiliation(s)
- Zhaokui Zeng
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
| | - Huimin Li
- Yueyang Inspection and Testing Center, Yueyang 414000, China
| | - Qi Li
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
| | - Ruowei Sun
- Hunan Zaochen Nanorobot Co., Ltd, Liuyang 410300, China
| | - Xun Zhang
- Hunan Zaochen Nanorobot Co., Ltd, Liuyang 410300, China
| | - Di Zhang
- Department of Laboratory, The Third Xiangya Hospital, Central South University, Changsha 410013, China
| | - Qubo Zhu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
| | - Chuanpin Chen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
| |
Collapse
|
2
|
Vaquer A, Adrover-Jaume C, Clemente A, Viana J, Rodríguez R, Rojo-Molinero E, Oliver A, de la Rica R. OriPlex: Origami-enabled multiplexed detection of respiratory pathogens. Biosens Bioelectron 2024; 257:116341. [PMID: 38677019 DOI: 10.1016/j.bios.2024.116341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 04/19/2024] [Accepted: 04/24/2024] [Indexed: 04/29/2024]
Abstract
Origami biosensors leverage paper foldability to develop total analysis systems integrated in a single piece of paper. This capability can also be utilized to incorporate additional features that would be difficult to achieve with rigid substrates. In this article, we report a new design for 3D origami biosensors called OriPlex, which leverages the foldability of filter paper for the multiplexed detection of bacterial pathogens. OriPlex immunosensors detect pathogens by folding nanoparticle reservoirs containing different types of nanoprobes. This releases antibody-coated nanoparticles in a central channel where targets are captured through physical interactions. The OriPlex concept was demonstrated by detecting the respiratory pathogens Pseudomonas aeruginosa (PA) and Klebsiella pneumoniae (KP) with a limit of detection of 3.4·103 cfu mL-1 and 1.4·102 cfu mL-1, respectively, and with a turn-around time of 25 min. Remarkably, the OriPlex biosensors allowed the multiplexed detection of both pathogens spiked into real bronchial aspirate (BAS) samples at a concentration of 105 cfu mL-1 (clinical infection threshold), thus demonstrating their suitability for diagnosing lower tract respiratory infections. The results shown here pave the way for implementing OriPlex biosensors as a screening test for detecting superbugs requiring personalized antibiotics in suspected cases of nosocomial pneumonia.
Collapse
Affiliation(s)
- Andreu Vaquer
- Multidisciplinary Sepsis Group, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma de Mallorca, Spain; Department of Chemistry, University of the Balearic Islands, Palma de Mallorca, Spain
| | - Cristina Adrover-Jaume
- Multidisciplinary Sepsis Group, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma de Mallorca, Spain; Department of Chemistry, University of the Balearic Islands, Palma de Mallorca, Spain
| | - Antonio Clemente
- Multidisciplinary Sepsis Group, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma de Mallorca, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III Madrid, Spain.
| | - Julia Viana
- Microbiology Department, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma, Spain
| | - Rocío Rodríguez
- Microbiology Department, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma, Spain
| | - Estrella Rojo-Molinero
- Microbiology Department, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III Madrid, Spain
| | - Antonio Oliver
- Microbiology Department, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III Madrid, Spain
| | - Roberto de la Rica
- Multidisciplinary Sepsis Group, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma de Mallorca, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III Madrid, Spain.
| |
Collapse
|
3
|
Santopolo G, Clemente A, Rojo-Molinero E, Fernández S, Álvarez MC, Oliver A, de la Rica R. Improved cytometric analysis of untouched lung leukocytes by enzymatic liquefaction of sputum samples. Biol Proced Online 2022; 24:17. [PMID: 36396988 PMCID: PMC9673301 DOI: 10.1186/s12575-022-00181-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Accepted: 11/02/2022] [Indexed: 11/19/2022] Open
Abstract
Background Phenotyping sputum-resident leukocytes and evaluating their functional status are essential analyses for exploring the cellular basis of pathological processes in the lungs, and flow cytometry is widely recognized as the gold-standard technique to address them. However, sputum-resident leukocytes are found in respiratory samples which need to be liquefied prior to cytometric analysis. Traditional liquefying procedures involve the use of a reducing agent such as dithiothreitol (DTT) in temperature-controlled conditions, which does not homogenize respiratory samples efficiently and impairs cell viability and functionality. Methods Here we propose an enzymatic method that rapidly liquefies samples by means of generating O2 bubbles with endogenous catalase. Sputum specimens from patients with suspected pulmonary infection were treated with DTT, the enzymatic method or PBS. We used turbidimetry to compare the liquefaction degree and cell counts were determined using a hemocytometer. Finally, we conducted a comparative flow cytometry study for evaluating frequencies of sputum-resident neutrophils, eosinophils and lymphocytes and their activation status after liquefaction. Results Enzymatically treated samples were better liquefied than those treated with DTT or PBS, which resulted in a more accurate cytometric analysis. Frequencies of all cell subsets analyzed within liquefied samples were comparable between liquefaction methods. However, the gentle cell handling rendered by the enzymatic method improves cell viability and retains in vivo functional characteristics of sputum-resident leukocytes (with regard to HLA-DR, CD63 and CD11b expression). Conclusion In conclusion, the proposed enzymatic liquefaction method improves the cytometric analysis of respiratory samples and leaves the cells widely untouched for properly addressing functional analysis of lung leukocytes. Supplementary Information The online version contains supplementary material available at 10.1186/s12575-022-00181-z.
Collapse
|
4
|
Khan J, Rasmi Y, Kırboğa KK, Ali A, Rudrapal M, Patekar RR. Development of gold nanoparticle-based biosensors for COVID-19 diagnosis. BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES 2022; 11:111. [PMID: 36092513 PMCID: PMC9444098 DOI: 10.1186/s43088-022-00293-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 08/30/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism of coronavirus disease 2019 (COVID-19) which poses a significant threat to public health worldwide. Though there are certain recommended drugs that can cure COVID-19, their therapeutic efficacy is limited. Therefore, the early and rapid detection without compromising the test accuracy is necessary in order to provide an appropriate treatment for the disease suppression.
Main body
Nanoparticles (NPs) can closely mimic the virus and interact strongly with its proteins due to their morphological similarities. NPs have been widely applied in a variety of medical applications, including biosensing, drug delivery, antimicrobial treatment, and imaging. Recently, NPs-based biosensors have attracted great interest for their biological activities and specific sensing properties, which allows the detection of analytes such as nucleic acids (DNA or RNA), aptamers, and proteins in clinical samples. Further, the advances of nanotechnologies have enabled the development of miniaturized detection systems for point-of-care biosensors, a new strategy for detecting human viral diseases. Among the various NPs, the specific physicochemical properties of gold NPs (AuNPs) are being widely used in the field of clinical diagnostics. As a result, several AuNP-based colorimetric detection methods have been developed.
Short conclusion
The purpose of this review is to provide an overview of the development of AuNPs-based biosensors by virtue of its powerful characteristics as a signal amplifier or enhancer that target pathogenic RNA viruses that provide a reliable and effective strategy for detecting of the existing or newly emerging SARS-CoV-2.
Collapse
|
5
|
Southworth T, Jackson N, Singh D. Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects. Eur Respir J 2022; 60:13993003.00497-2022. [PMID: 35728975 PMCID: PMC9403393 DOI: 10.1183/13993003.00497-2022] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 06/06/2022] [Indexed: 11/26/2022]
Abstract
COPD patients have a higher risk of developing severe illness and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. Vaccination protects against coronavirus disease 2019 (COVID-19) through the development of systemic and airway immune responses. Patients with COPD display altered humoral immunity, with reduced antibody responses compared to healthy controls [2, 3]. We studied SARS-CoV-2 vaccine-specific immune responses in COPD patients versus healthy controls, using systemic, nasal and sputum samples. Airway and blood immune responses to COVID-19 vaccination were examined in COPD patients and healthy subjects. Anti-spike IgG, but not IgA, levels were higher in airways post-vaccination, with similar responses in COPD patients and healthy subjects. https://bit.ly/3zt6D6v
Collapse
Affiliation(s)
- Thomas Southworth
- University of Manchester, Division of Infection, Immunity and Respiratory Medicine, Manchester University NHS Foundation Trust, Manchester, UK .,Medicines Evaluation Unit, Manchester, UK
| | | | - Dave Singh
- University of Manchester, Division of Infection, Immunity and Respiratory Medicine, Manchester University NHS Foundation Trust, Manchester, UK.,Medicines Evaluation Unit, Manchester, UK
| |
Collapse
|
6
|
Eddins DJ, Bassit LC, Chandler JD, Haddad NS, Musall KL, Yang J, Kosters A, Dobosh BS, Hernández MR, Ramonell RP, Tirouvanziam RM, Lee FEH, Zandi K, Schinazi RF, Ghosn EEB. Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies. Immunohorizons 2022; 6:144-155. [PMID: 35173021 PMCID: PMC9164212 DOI: 10.4049/immunohorizons.2200005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 01/24/2022] [Indexed: 01/13/2023] Open
Abstract
Due to the severity of COVID-19 disease, the U.S. Centers for Disease Control and Prevention and World Health Organization recommend that manipulation of active viral cultures of SARS-CoV-2 and respiratory secretions from COVID-19 patients be performed in biosafety level (BSL)3 laboratories. Therefore, it is imperative to develop viral inactivation procedures that permit samples to be transferred to lower containment levels (BSL2), while maintaining the fidelity of complex downstream assays to expedite the development of medical countermeasures. In this study, we demonstrate optimal conditions for complete viral inactivation following fixation of infected cells with commonly used reagents for flow cytometry, UVC inactivation in sera and respiratory secretions for protein and Ab detection, heat inactivation following cDNA amplification for droplet-based single-cell mRNA sequencing, and extraction with an organic solvent for metabolomic studies. Thus, we provide a suite of viral inactivation protocols for downstream contemporary assays that facilitate sample transfer to BSL2, providing a conceptual framework for rapid initiation of high-fidelity research as the COVID-19 pandemic continues.
Collapse
Affiliation(s)
- Devon J Eddins
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA
| | - Leda C Bassit
- Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
| | - Joshua D Chandler
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; and
| | - Natalie S Haddad
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA
| | - Kathryn L Musall
- Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
| | - Junkai Yang
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA
| | - Astrid Kosters
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA
| | - Brian S Dobosh
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; and
| | - Mindy R Hernández
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA
| | - Richard P Ramonell
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA
| | - Rabindra M Tirouvanziam
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Center for Cystic Fibrosis and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; and
| | - F Eun-Hyung Lee
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA
| | - Keivan Zandi
- Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
| | - Raymond F Schinazi
- Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
| | - Eliver E B Ghosn
- Lowance Center for Human Immunology, Division of Immunology and Rheumatology, Department of Medicine, Emory University School of Medicine, Atlanta, GA;
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA
| |
Collapse
|
7
|
Clemente A, Alba-Patiño A, Santopolo G, Barón E, Rojo-Molinero E, Oliver A, Pérez-Bárcena J, Merino de Cos P, Aranda M, Del Castillo A, Socias A, Borges M, de la Rica R. Optimized detection of lung IL-6 via enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients. Analyst 2021; 146:6537-6546. [PMID: 34581315 DOI: 10.1039/d1an00763g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Lung IL-6 is a promising biomarker for predicting respiratory failure during pulmonary infections. This biomarker is found in respiratory samples which need to be liquefied prior to analysis. Traditional liquefying methods use reducing agents such as dithiothreitol (DTT). However, DTT impairs immunodetection and does not liquefy highly viscous samples. We propose an enzymatic method that liquefies samples by means of generating O2 bubbles with endogenous catalase. Low respiratory tract specimens from 48 mechanically ventilated patients (38 with SARS-CoV-2 infection) were treated with DTT or with the enzymatic method. We used turbidimetry to compare the liquefaction degree and IL-6 was quantified with ELISA. Finally, we used AUC-ROC, time-to-event and principal component analysis to evaluate the association between respiratory compromise or local inflammation and IL-6 determined with both methods. Enzymatically treated samples were better liquefied than those reduced by DTT, which resulted in higher ELISA signals. Lung IL-6 levels obtained with the enzymatic procedure were negatively correlated with the oxygenation index (PaO2/FiO2) and the time of mechanical ventilation. The proposed enzymatic liquefaction method improves the sensitivity for lung IL-6 detection in respiratory samples, which increases its predictive power as a biomarker for evaluating respiratory compliance.
Collapse
Affiliation(s)
- Antonio Clemente
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
| | - Alejandra Alba-Patiño
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. .,Balearic Islands University, Chemistry Department, Palma de Mallorca, Spain
| | - Giulia Santopolo
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. .,Balearic Islands University, Chemistry Department, Palma de Mallorca, Spain
| | - Enrique Barón
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
| | - Estrella Rojo-Molinero
- Microbiology Department, Son Espases University Hospital, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - Antonio Oliver
- Microbiology Department, Son Espases University Hospital, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain
| | - Jon Pérez-Bárcena
- Intensive Care Department, Son Espases University Hospital, Palma de Mallorca, Spain
| | | | - María Aranda
- Multidisciplinary Sepsis Unit, ICU, Son Llàtzer University Hospital, Palma de Mallorca, Spain
| | - Alberto Del Castillo
- Multidisciplinary Sepsis Unit, ICU, Son Llàtzer University Hospital, Palma de Mallorca, Spain
| | - Antonia Socias
- Multidisciplinary Sepsis Unit, ICU, Son Llàtzer University Hospital, Palma de Mallorca, Spain
| | - Marcio Borges
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. .,Multidisciplinary Sepsis Unit, ICU, Son Llàtzer University Hospital, Palma de Mallorca, Spain
| | - Roberto de la Rica
- Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. .,Balearic Islands University, Chemistry Department, Palma de Mallorca, Spain
| |
Collapse
|
8
|
Beduk T, Beduk D, de Oliveira Filho JI, Zihnioglu F, Cicek C, Sertoz R, Arda B, Goksel T, Turhan K, Salama KN, Timur S. Rapid Point-of-Care COVID-19 Diagnosis with a Gold-Nanoarchitecture-Assisted Laser-Scribed Graphene Biosensor. Anal Chem 2021; 93:8585-8594. [PMID: 34081452 PMCID: PMC8189039 DOI: 10.1021/acs.analchem.1c01444] [Citation(s) in RCA: 91] [Impact Index Per Article: 30.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 05/20/2021] [Indexed: 12/17/2022]
Abstract
The global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has revealed the urgent need for accurate, rapid, and affordable diagnostic tests for epidemic understanding and management by monitoring the population worldwide. Though current diagnostic methods including real-time polymerase chain reaction (RT-PCR) provide sensitive detection of SARS-CoV-2, they require relatively long processing time, equipped laboratory facilities, and highly skilled personnel. Laser-scribed graphene (LSG)-based biosensing platforms have gained enormous attention as miniaturized electrochemical systems, holding an enormous potential as point-of-care (POC) diagnostic tools. We describe here a miniaturized LSG-based electrochemical sensing scheme for coronavirus disease 2019 (COVID-19) diagnosis combined with three-dimensional (3D) gold nanostructures. This electrode was modified with the SARS-CoV-2 spike protein antibody following the proper surface modifications proved by X-ray photoelectron spectroscopy (XPS) and scanning electron microscopy (SEM) characterizations as well as electrochemical techniques. The system was integrated into a handheld POC detection system operated using a custom smartphone application, providing a user-friendly diagnostic platform due to its ease of operation, accessibility, and systematic data management. The analytical features of the electrochemical immunoassay were evaluated using the standard solution of S-protein in the range of 5.0-500 ng/mL with a detection limit of 2.9 ng/mL. A clinical study was carried out on 23 patient blood serum samples with successful COVID-19 diagnosis, compared to the commercial RT-PCR, antibody blood test, and enzyme-linked immunosorbent assay (ELISA) IgG and IgA test results. Our test provides faster results compared to commercial diagnostic tools and offers a promising alternative solution for next-generation POC applications.
Collapse
Affiliation(s)
- Tutku Beduk
- Sensors Lab, Advanced Membranes and Porous Materials
Center, Computer, Electrical and Mathematical Science and Engineering Division,
King Abdullah University of Science and Technology (KAUST),
Thuwal 23955-6900, Saudi Arabia
| | - Duygu Beduk
- Central Research Test and Analysis Laboratory
Application and Research Center, Ege University, 35100 Bornova,
Izmir, Turkey
| | - José Ilton de Oliveira Filho
- Sensors Lab, Advanced Membranes and Porous Materials
Center, Computer, Electrical and Mathematical Science and Engineering Division,
King Abdullah University of Science and Technology (KAUST),
Thuwal 23955-6900, Saudi Arabia
| | - Figen Zihnioglu
- Department of Biochemistry, Faculty of Science,
Ege University, 35100 Bornova, Izmir,
Turkey
| | - Candan Cicek
- Department of Medical Microbiology, Faculty of
Medicine, Ege University, 35100 Bornova, Izmir,
Turkey
| | - Ruchan Sertoz
- Department of Medical Microbiology, Faculty of
Medicine, Ege University, 35100 Bornova, Izmir,
Turkey
| | - Bilgin Arda
- Department of Infectious Diseases and Clinical
Microbiology, Faculty of Medicine, Ege University, 35100
Bornova, Izmir, Turkey
| | - Tuncay Goksel
- Department of Pulmonary Medicine, Faculty of Medicine,
Ege University, 35100 Bornova, Izmir,
Turkey
- EGESAM-Ege University Translational
Pulmonary Research Center, 35100 Bornova, Izmir,
Turkey
| | - Kutsal Turhan
- Department of Thoracic Surgery, Faculty of Medicine,
Ege University, 35100 Bornova, Izmir,
Turkey
| | - Khaled N. Salama
- Sensors Lab, Advanced Membranes and Porous Materials
Center, Computer, Electrical and Mathematical Science and Engineering Division,
King Abdullah University of Science and Technology (KAUST),
Thuwal 23955-6900, Saudi Arabia
| | - Suna Timur
- Central Research Test and Analysis Laboratory
Application and Research Center, Ege University, 35100 Bornova,
Izmir, Turkey
- Department of Biochemistry, Faculty of Science,
Ege University, 35100 Bornova, Izmir,
Turkey
| |
Collapse
|